Context Therapeutics amends BioAtla license deal for CT-202 drug
Go back to Context Therapeutics amends BioAtla license deal for CT-202 drug| (NASDAQ: BCAB) | Delayed: 3.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.18 | 52 Week High | $ | |||
| Open | $3.26 | 52 Week Low | $ | |||
| Day High | $3.41 | P/E | N/A | |||
| Day Low | $3.03 | EPS | $ | |||
| Volume | 88,745 | |||||
| (NASDAQ: CNTX) | Delayed: 0.50 -0.02 (3.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.52 | 52 Week High | $ | |||
| Open | $0.53 | 52 Week Low | $ | |||
| Day High | $0.55 | P/E | N/A | |||
| Day Low | $0.50 | EPS | $ | |||
| Volume | 1,747,422 | |||||
